Total Payments
$4,740
2024 Payments
$927.88
Companies
25
Transactions
192
Medicare Patients
4,795
Medicare Billing
$1.5M
Payment Breakdown by Category
Food & Beverage$4,608 (97.2%)
Education$132.40 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,608 | 188 | 97.2% |
| Education | $132.40 | 4 | 2.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fresenius USA Marketing, Inc. | $971.49 | 44 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $580.72 | 26 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $547.25 | 20 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $515.18 | 17 | $0 (2019) |
| GlaxoSmithKline, LLC. | $296.93 | 14 | $0 (2022) |
| Amgen Inc. | $225.52 | 11 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $196.30 | 9 | $0 (2023) |
| AKEBIA THERAPEUTICS INC | $175.57 | 8 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $174.74 | 3 | $0 (2024) |
| Vifor Pharma, Inc. | $157.05 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $927.88 | 30 | Bayer Healthcare Pharmaceuticals Inc. ($260.51) |
| 2023 | $347.84 | 11 | AstraZeneca Pharmaceuticals LP ($169.49) |
| 2022 | $723.60 | 34 | Vifor Pharma, Inc. ($157.05) |
| 2021 | $534.40 | 27 | GlaxoSmithKline, LLC. ($174.74) |
| 2020 | $276.03 | 14 | AstraZeneca Pharmaceuticals LP ($96.81) |
| 2019 | $742.15 | 28 | Mallinckrodt Enterprises LLC ($179.85) |
| 2018 | $832.04 | 34 | Fresenius USA Marketing, Inc. ($340.12) |
| 2017 | $356.46 | 14 | Novartis Pharmaceuticals Corporation ($111.00) |
All Payment Transactions
192 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.44 | General |
| Category: Cardio-renal | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/01/2024 | IBSA Pharma Inc. | Tirosint (Drug), Licart | Food and Beverage | Cash or cash equivalent | $24.98 | General |
| Category: Endocrinology | ||||||
| 09/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $31.35 | General |
| Category: Cardio-renal | ||||||
| 09/03/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/20/2024 | AKEBIA THERAPEUTICS INC | Auryxia (Drug), Vafseo | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: Nephrology | ||||||
| 08/20/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $31.50 | General |
| Category: Cardio-renal | ||||||
| 07/25/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $122.95 | General |
| Category: Diabetes | ||||||
| 06/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Cardio-renal | ||||||
| 06/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Cardio-renal | ||||||
| 05/23/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Phosphate binder for ESRD | ||||||
| 05/20/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/13/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/07/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $31.96 | General |
| Category: Cardio-renal | ||||||
| 04/15/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GATTEX (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: INTERNAL MEDICINE | ||||||
| 03/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.87 | General |
| Category: Cardio-renal | ||||||
| 03/07/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 02/21/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.01 | General |
| Category: Phosphate binder for ESRD | ||||||
| 02/06/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $33.74 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 904 | 2,477 | $574,610 | $243,672 |
| 2022 | 16 | 1,034 | 3,186 | $823,906 | $342,419 |
| 2021 | 15 | 2,357 | 3,899 | $1.2M | $485,254 |
| 2020 | 10 | 500 | 2,180 | $1.2M | $401,149 |
Total Patients
4,795
Total Services
11,742
Medicare Billing
$1.5M
Procedure Codes
57
All Medicare Procedures & Services
57 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 74 | 402 | $281,400 | $124,472 | 44.2% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 181 | 828 | $69,959 | $35,897 | 51.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 121 | 508 | $46,401 | $23,541 | 50.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 116 | 139 | $34,820 | $14,312 | 41.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 89 | 111 | $38,515 | $8,743 | 22.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 69 | 82 | $12,784 | $5,889 | 46.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 69 | $20,700 | $4,843 | 23.4% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 13 | 17 | $8,439 | $4,523 | 53.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 51 | 66 | $6,035 | $3,774 | 62.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 23 | $16,100 | $3,642 | 22.6% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 20 | 57 | $17,100 | $3,562 | 20.8% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 50 | 78 | $4,418 | $2,723 | 61.6% |
| 99349 | Residence visit for established patient with moderate level of medical decision making, per day, if using time, at least 40 minutes | Office | 2023 | 11 | 22 | $4,011 | $2,490 | 62.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 42 | 52 | $8,020 | $2,200 | 27.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 11 | 11 | $1,784 | $1,639 | 91.9% |
| 99344 | Residence visit for new patient with moderate level of medical decision making, per day, if using time, at least 60 minutes | Office | 2023 | 12 | 12 | $4,125 | $1,421 | 34.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 101 | 564 | $394,800 | $183,238 | 46.4% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 188 | 736 | $48,072 | $34,323 | 71.4% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 146 | 639 | $53,107 | $34,270 | 64.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 92 | 349 | $104,700 | $23,002 | 22.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 77 | 91 | $63,700 | $16,853 | 26.5% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 47 | 166 | $49,800 | $11,175 | 22.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 102 | $40,800 | $9,703 | 23.8% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 76 | 156 | $8,546 | $5,927 | 69.4% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 45 | 102 | $7,929 | $5,855 | 73.8% |
About Dr. Leon Shein, MD
Dr. Leon Shein, MD is a Nephrology healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1215004858.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leon Shein, MD has received a total of $4,740 in payments from pharmaceutical and medical device companies, with $927.88 received in 2024. These payments were reported across 192 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($4,608).
As a Medicare-enrolled provider, Shein has provided services to 4,795 Medicare beneficiaries, totaling 11,742 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 57 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Brooklyn, NY
- Active Since 11/29/2006
- Last Updated 06/10/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1215004858
Products in Payments
- Velphoro (Drug) $880.56
- ACTHAR (Biological) $588.42
- Kerendia (Drug) $547.25
- LOKELMA (Drug) $536.23
- BENLYSTA (Biological) $296.93
- Auryxia (Drug) $202.78
- JYNARQUE (Drug) $196.30
- Parsabiv (Biological) $138.49
- Rituxan (Biological) $136.05
- GATTEX (Drug) $127.44
- MOUNJARO (Drug) $122.95
- ENTRESTO (Drug) $111.00
- Dialyzers (Device) $75.57
- Veltassa (Drug) $71.70
- IBSRELA (Drug) $57.82
- AURYXIA (Drug) $56.86
- Parsabiv (Drug) $46.86
- FARXIGA (Drug) $44.49
- KRYSTEXXA (Drug) $37.39
- Thiola (Drug) $34.72
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Brooklyn
Gregg Miller, Md, MD
Nephrology — Payments: $57,485
Nephrology $57,485
Alla Maslova
Nephrology — Payments: $18,516
Nephrology $18,516
Li Yang, Md, MD
Nephrology — Payments: $17,726
Nephrology $17,726
Dr. Louis Carrera, Md, MD
Nephrology — Payments: $17,135
Nephrology $17,135
Dr. Mariana Markell, M.d, M.D
Nephrology — Payments: $15,506
Nephrology $15,506
Dr. Alan Nissenbaum, Md, MD
Nephrology — Payments: $15,228
Nephrology $15,228